Freedom Capital Markets has initiated coverage on Enovis Corp (ENOV) with a Buy rating, marking the firm's first assessment of the company's investment potential. The rating reflects an analysis of Enovis's business model, industry dynamics, and growth prospects.
Enovis operates as a medical technology growth company, headquartered in Wilmington, Delaware. With a workforce of 7,367 employees, the company specializes in developing clinically differentiated solutions through high-quality medical devices. These products cater to various applications, including reconstructive surgery, rehabilitation, pain management, and physical therapy. Enovis's operations are divided into two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment offers orthopedic solutions, while the Reconstructive segment focuses on surgical implant solutions.
As of December 16, 2025, Enovis shares are priced at $27.31, with a market capitalization of $1.7 billion. The company reported an EPS (TTM) of -24.20. Upcoming earnings are scheduled for May 6, 2026, with an estimated EPS of $0.79 and revenue of $593.3 million, followed by another report on August 5, 2026, with an estimated EPS of $0.87 and revenue of $604.3 million.
Analyst ratings, including this new Buy designation, serve as professional assessments based on research and financial models. However, they are contingent on various assumptions and estimates that may not always materialize. Investors should consider a range of factors, including company fundamentals and industry trends, when making decisions. It is also important to note that analyst opinions can evolve as new information emerges, leading to potential changes in ratings over time.